UPCC 03418: A Phase 1 First in Human Open Label Dose Escalation Study of AMV564 a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Enrolling By Invitation
99 years or below
All
Phase
1
10 participants needed
1 Location
Brief description of study
Amphivena Therapeutics, Inc. (Amphivena) is studying an investigational drug called AMV564, which may help to treat acute myeloid leukemia (AML). The purpose of this clinical research study is to find the highest tolerable dose that can be given to patients with AML, and to recommend a dose to be used in future studies. Another purpose of the study is to learn more about the safety of this drug and how the body processes the study drug.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Leukemia
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 829245
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
